Universal Beteiligungs und Servicegesellschaft mbH Invests $381,000 in Savara Inc. (NASDAQ:SVRA)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH invested approximately $381,000 to acquire a new stake in Savara Inc., acquiring 137,694 shares, reflecting only 0.08% of the total shares at the end of the reporting period.
• Other institutional investors have also increased their stakes in Savara, with Vanguard Group Inc. owning over $25 million and JPMorgan Chase & Co. growing their stake by nearly 2,000% in the last quarter.
• Savara is a clinical-stage pharmaceutical company focusing on treatments for rare respiratory diseases, and it reported earnings per share of ($0.12) in its last quarterly earnings, meeting analysts' expectations.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Savara Inc. (NASDAQ:SVRA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 137,694 shares of the company's stock, valued at approximately $381,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.08% of Savara at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in shares of Savara in the fourth quarter worth $34,000. Ameriprise Financial Inc. purchased a new stake in shares of Savara in the 4th quarter valued at $37,000. KLP Kapitalforvaltning AS purchased a new position in Savara in the 4th quarter worth approximately $41,000. Hsbc Holdings PLC bought a new position in shares of Savara during the fourth quarter valued at approximately $48,000. Finally, Jump Financial LLC purchased a new stake in Savara in the fourth quarter worth $64,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SVRA. Guggenheim reissued a "buy" rating and set a $8.00 price target (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. HC Wainwright downgraded shares of Savara from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $6.00 to $2.00 in a report on Thursday, May 29th. Wells Fargo & Company lowered their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Finally, Evercore ISI decreased their target price on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research report on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, Savara has a consensus rating of "Moderate Buy" and a consensus target price of $5.60.

Savara Trading Up 5.1%

Shares of SVRA traded up $0.13 during midday trading on Tuesday, reaching $2.70. The company had a trading volume of 842,739 shares, compared to its average volume of 958,516. The company has a quick ratio of 14.91, a current ratio of 14.91 and a debt-to-equity ratio of 0.20. The firm has a 50 day simple moving average of $2.31 and a 200-day simple moving average of $2.66. Savara Inc. has a 1-year low of $1.89 and a 1-year high of $4.70. The stock has a market cap of $466.67 million, a PE ratio of -5.62 and a beta of 0.40.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Research analysts forecast that Savara Inc. will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling at Savara

In other Savara news, Director Richard J. Hawkins bought 48,225 shares of the business's stock in a transaction on Friday, June 20th. The stock was bought at an average price of $2.04 per share, for a total transaction of $98,379.00. Following the completion of the transaction, the director owned 115,466 shares in the company, valued at approximately $235,550.64. The trade was a 71.72% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.13% of the stock is currently owned by company insiders.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.